Infliximab for refractory ulcerative colitis or indeterminate colitis: an open-label multicentre study.

Gornet, J-M; Couve, S; Hassani, Z; Delchier, J-C; Marteau, P; Cosnes, J; Bouhnik, Y; Dupas, J-L; Modigliani, R; Taillard, F; Lemann, M

Gornet, J-M; Couve, S; Hassani, Z; Delchier, J-C; Marteau, P; Cosnes, J; Bouhnik, Y; Dupas, J-L; Modigliani, R; Taillard, F; Lemann, M.

Afiliación

Gornet JM; Department of Gastroenterology, Hôpital Saint-Louis, Paris, France. jean-marc.gornet@sls.ap-hop-paris.fr

Aliment Pharmacol Ther ; 18(2): 175-81, 2003 Jul 15.

Article en En | MEDLINE | ID: mdl-12869077

RESUMEN

BACKGROUND: The efficacy of infliximab in ulcerative colitis (UC) and indeterminate colitis has been poorly assessed and preliminary results are conflicting. METHODS: The records of 30 patients treated with infliximab for ulcerative colitis (n=19) or indeterminate colitis (n=11) were reviewed. Infliximab was given because of steroid resistance (n=18), dependence (n=5) or intolerance (n=7); five patients had failed on cyclosporin; 19 patients had a severe flare-up. RESULTS: Median duration of follow-up was 10 months. In 28 patients with active disease, the response rate was 75% at day 7, with 43% having a complete remission, and 50% at month 1, with 32% having a complete remission. Among the 22 responders, the probability of relapse was 73% at month 6. The probability of complete remission without steroids, taking into account the re-treatment for relapse (n=11), was 57% (95% confidence interval (CI): 45% to 69%) at month 6. The probability of colectomy was 33% (95% CI: 23% to 43%) at month 12. In indeterminate colitis, response rate was only 50% at day 7 and 30% at month 1. Concomitant use of antimetabolite agents was associated with better results. CONCLUSIONS: Infliximab was able to induce a rapid response in some patients with UC or indeterminate colitis refractory to conventional treatment. Long-term results were less favourable, with frequent relapses, and about one-third of the patients required a colectomy.

Asunto(s)

Anticuerpos Monoclonales/uso terapéutico; Colitis/tratamiento farmacológico; Fármacos Gastrointestinales/uso terapéutico; Adolescente; Adulto; Anciano; Enfermedad Crónica; Estudios de Cohortes; Colectomía; Colitis Ulcerosa/tratamiento farmacológico; Femenino; Humanos; Infliximab; Masculino; Persona de Mediana Edad; Recurrencia; Inducción de Remisión; Estudios Retrospectivos; Resultado del Tratamiento

Buscar en Google

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Fármacos Gastrointestinales / Colitis / Anticuerpos Monoclonales Tipo de estudio: Etiology_studies / Incidence_studies / Observational_studies / Risk_factors_studies Límite: Adolescent / Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Aliment Pharmacol Ther Asunto de la revista: FARMACOLOGIA / GASTROENTEROLOGIA / TERAPIA POR MEDICAMENTOS Año: 2003 Tipo del documento: Article País de afiliación: Francia Pais de publicación: Reino Unido

Buscar en Google

Añadir a Mi BVS

Imprimir

XML

PubMed Links